Racial Comparisons in Timeliness of Colon Cancer Treatment in an Equal-Access Health System

Journal of the National Cancer Institute

Volumn 112, Issue 4, 2020, Pages 410-417

  Eaglehouse, Yvonne L ^a,b   Georg, Matthew W ^a   Shriver, Craig D ^a,b   Zhu, Kangmin ^a,b  

^a Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^b Department of Surgery ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGISTRY; CANCER SURGERY; COLON ADENOCARCINOMA; CONFIDENCE INTERVAL; DATA BASE; FEMALE; HEALTH CARE ACCESS; HEALTH CARE DISPARITY; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MILITARY HEALTH; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; ODDS RATIO; PRIORITY JOURNAL; RACE DIFFERENCE; THERAPY DELAY; TIME TO TREATMENT; ADOLESCENT; BLACK PERSON; CAUCASIAN; COLON TUMOR; COMPARATIVE STUDY; ETHNOLOGY; HEALTH CARE DELIVERY; PATHOLOGY; REGISTER; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; COLONIC NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; MIDDLE AGED; REGISTRIES; TIME-TO-TREATMENT; UNITED STATES; YOUNG ADULT;

EID: 85077926510     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djz135     Document Type: Article

References (69)

1. White A, Joseph D, Rim SH, Johnson CJ, Coleman MP, Allemani C. Colon cancer survival in the United States by race and stage (2001-2009): findings from the CONCORD-2 study. Cancer. 2017;123(suppl 24):5014-5036.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34.
3. American Cancer Society. Cancer Facts &Figures, 2019. Atlanta, GA: American Cancer Society; 2019. https://www.cancer.org/research/cancer-facts-statistics. html. Accessed January 11, 2019.
4. Alexander DD, Waterbor J, Hughes T, Funkhouser E, Grizzle W, Manne U. African-American and Caucasian disparities in colorectal cancer mortality and survival by data source: an epidemiologic review. Cancer Biomark. 2007; 3(6):301-313.
5. Lai Y, Wang C, Civan JM, et al. Effects of cancer stage and treatment differences on racial disparities in survival from colon cancer: a United States population-based study. Gastroenterology. 2016;150(5):1135-1146.
6. Gorey KM, Kanjeekal SM, Wright FC, et al. Colon cancer care and survival: income and insurance are more predictive in the USA, community primary care physician supply more so in Canada. Int J Equity Health. 2015;14(1):109.
7. Tammana VS, Laiyemo AO. Colorectal cancer disparities: issues, controversies and solutions. World J Gastroenterol. 2014;20(4):869-876.
8. Sineshaw HM, Ng K, Flanders WD, Brawley OW, Jemal A. Factors that contribute to differences in survival of black vs white patients with colorectal cancer. Gastroenterology. 2018;154(4):906-915.e7.
9. Pulte D, Jansen L, Brenner H. Social disparities in survival after diagnosis with colorectal cancer: contribution of race and insurance status. Cancer Epidemiol 2017;48:41-47.
10. Neal RD, Tharmanathan P, France B, et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br J Cancer. 2015;112(suppl 1):S92-S107.
11. Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA. 2011;305(22): 2335-2342.
12. Des Guetz G, Nicolas P, Perret G-Y, Morere J-F, Uzzan B. Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis. Eur J Cancer. 2010;46(6):1049-1055.
13. Amri R, Bordeianou LG, Sylla P, Berger DL. Treatment delay in surgicallytreated colon cancer: Does it affect outcomes? Ann Surg Oncol. 2014;21(12): 3909-3916.
14. Czaykowski PM, Gill S, Kennecke HF, Gordon VL, Turner D. Adjuvant chemotherapy for stage III colon cancer: Does timing matter? Dis Colon Rectum. 2011; 54(9):1082-1089.
15. Nachiappan S, Askari A, Mamidanna R, et al. The impact of adjuvant chemotherapy timing on overall survival following colorectal cancer resection. Eur J Surg Oncol. 2015;41(12):1636-1644.
16. Bos AC, van Erning FN, van Gestel YR, et al. Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer. Eur J Cancer. 2015;51(17):2553-2561.
17. Roland CL, Schwarz RE, Tong L, et al. Is timing to delivery of treatment a reliable measure of quality of care for patients with colorectal adenocarcinoma? Surgery. 2013;154(3):421-428.
18. Cronin DP, Harlan LC, Potosky AL, Clegg LX, Stevens JL, Mooney MM. Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Am J Gastroenterology. 2006;101(10): 2308-2318.
19. Hines RB, Barrett A, Twumasi-Ankrah P, et al. Predictors of guideline treatment nonadherence and the impact on survival in patients with colorectal cancer. J Natl Compr Canc Netw. 2015;13(1):51-60.
20. Boland GM, Chang GJ, Haynes AB, et al. Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer. Cancer. 2013;119(8):1593-1601.
21. Hershman D, Hall MJ, Wang X, et al. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer. 2006;107(11):2581-2588.
22. Jones LA, Ferrans CE, Polite BN, et al. Examining racial disparities in colon cancer clinical delay in the colon cancer patterns of care in Chicago study. Ann Epidemiol. 2017;27(11):731-738.e1.
23. Baldwin LM, Dobie SA, Billingsley K, et al. Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst. 2005; 97(16):1211-1220.
24. Dimou A, Syrigos KN, Saif MW. Disparities in colorectal cancer in African-Americans vs whites: before and after diagnosis. World J Gastroenterol. 2009; 15(30):3734-3743.
25. Demissie K, Oluwole OO, Balasubramanian BA, Osinubi OO, August D, Rhoads GG. Racial differences in the treatment of colorectal cancer: a comparison of surgical and radiation therapy between whites and blacks. Ann Epidemiol. 2004;14(3):215-221.
26. Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol. 2002;20(5):1192-1202.
27. Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94(5):334-357.
28. Berry J, Bumpers K, Ogunlade V, et al. Examining racial disparities in colorectal cancer care. J Psychosoc Oncol. 2009;27(1):59-83.
29. Bilimoria KY, Ko CY, Tomlinson JS, et al. Wait times for cancer surgery in the United States: trends and predictors of delays. Ann Surg. 2011;253(4):779-785.
30. Adamson AS, Zhou L, Baggett CD, Thomas NE, Meyer AM. Association of delays in surgery for melanoma with insurance type. JAMA Dermatol. 2017; 153(11):1106-1113.
31. Bestvina CM, Zullig LL, Yousuf Zafar S. The implications of out-of-pocket cost of cancer treatment in the USA: a critical appraisal of the literature. Future Oncol. 2014;10(14):2189-2199.
32. Abdelsattar ZM, Hendren S, Wong SL. The impact of health insurance on cancer care in disadvantaged communities. Cancer. 2017;123(7):1219-1227.
33. Chagpar R, Xing Y, Chiang YJ, et al. Adherence to stage-specific treatment guidelines for patients with colon cancer. J Clin Oncol. 2012;30(9):972-979.
34. Bouwman F, Smits A, Lopes A, et al. The impact of BMI on surgical complications and outcomes in endometrial cancer surgery-an institutional study and systematic review of the literature. Gynecol Oncol. 2015;139(2): 369-376.
35. Antonio M, Carmona-Bayonas A, Saldana J, et al. Factors predicting adherence to a tailored-dose adjuvant treatment on the basis of geriatric assessment in elderly people with colorectal cancer: a prospective study. Clin Colorectal Cancer. 2018;17(1):e59-e68.
36. Lin C, Clark R, Tu P, Bosworth HB, Zullig LL. Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers. Breast Cancer Res Treat. 2017;165(2):247-260.
37. Grant SR, Walker GV, Guadagnolo BA, Koshy M, Allen PK, Mahmood U. Variation in insurance status by patient demographics and tumor site among nonelderly adult patients with cancer. Cancer. 2015;121(12): 2020-2028.
38. Mayberry RM, Mili F, Ofili E. Racial and ethnic differences in access to medical care. Med Care Res Rev. 2000;57(suppl 1):108-145.
39. Wheeler SM, Bryant AS. Racial and ethnic disparities in health and health care. Obstet Gynecol Clin North Am. 2017;44(1):1-11.
40. Health.mil. Falls Church, VA: Defense Health Agency. https://www.health. mil/About-MHS/OASDHA/Defense-Health-Agency. Accessed January 31, 2019.
41. Defense Health Agency Decision Support Division. Evaluation of the TRICARE Program: Fiscal year 2018 report to Congress. 2018. https://health. mil/Military-Health-Topics/Access-Cost-Quality-and-Safety/Health-Care-Program-Evaluation/Annual-Evaluation-of-The-TRICARE-Program. Accessed April 25, 2019.
42. Defense Health Agency. TRICARE. www.tricare.mil. Accessed April 5, 2019.
43. Enewold L, Zhou J, McGlynn KA, et al. Racial variation in breast cancer treatment among Department of Defense beneficiaries. Cancer. 2012;118(3): 812-820.
44. Gill AA, Enewold L, Zahm SH, et al. Colon cancer treatment: are there racial disparities in an equal-access healthcare system? Dis Colon Rectum. 2014; 57(9):1059-1065.
45. The Department of Defense Joint Pathology Center. DoD Cancer Registry Program. 2014. https://www.jpc.capmed.mil/education/dodccrs/index.asp. Accessed April 5, 2019.
46. North American Association of Central Cancer Registries. Central Registry Standards. 2018. https://www.naaccr.org. Accessed April 25, 2019.
47. Defense Health Agency. Military Health System Data Repository. https:// www.health.mil/Military-Health-Topics/Technology/Clinical-Support/ Military-Health-System-Data-Repository. Accessed October 26, 2017.
48. D'Souza N, de Neree Tot Babberich MPM, Lord A, et al. The rectosigmoid problem. Surg Oncol. 2018;27(3):521-525.
49. Desch CE, McNiff KK, Schneider EC, et al. American Society of Clinical Oncology/National Comprehensive Cancer Network quality measures. J Clin Oncol. 2008;26(21):3631-3637.
50. National Comprehensive Cancer Network. Colon Cancer, version 1.2018. Clinical Practice Guidelines in Oncology (NCCN Guidelines). 2018. https:// www.NCCN.org. Accessed March 1, 2018.
51. van de Velde CJ, Boelens PG, Borras JM, et al. EURECCA colorectal: multidisciplinary management: European consensus conference colon &rectum. Eur J Cancer. 2014;50(1):1.e1-1.e34.
52. Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012;23(10):2479-2516.
53. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. Chicago, IL: Springer; 2002.
54. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene GL, Triotti A. AJCC Cancer Staging Manual. 7th ed. Chicago, IL: Springer; 2010.
55. Engstrom PF, Arnoletti JP, Benson AB III, et al. NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw. 2009;7(8): 778-831.
56. Benson AB III, Bekaii-Saab T, Chan E, et al. Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013;11(5):519-528.
57. Benson AB III, Venook AP, Bekaii-Saab T, et al. Colon cancer, version 3.2014. J Natl Compr Canc Netw. 2014;12(7):1028-1059.
58. Eaglehouse YL, Georg MW, Richard P, Shriver CD, Zhu K. Costs for colon cancer treatment comparing benefit types and care sources in the U.S. Military Health System. Mil Med. 2019:1-9; doi: 10.1093/milmed/usz065.
59. Cancer Care Ontario. Target wait times for cancer surgery in Ontario. https:// www.cancercareontario.ca/en/content/target-wait-times-cancer-surgeryontario. Accessed March 1, 2018.
60. National Health Service England. Delivering Cancer Waiting Times: A Good Practice Guide. 2014. https://www.england.nhs.uk/wp-content/uploads/2015/ 03/delivering-cancer-wait-times.pdf. Accessed March 5, 2018.
61. Beets G, Sebag-Montefiore D, Andritsch E, et al. ECCO essential requirements for quality cancer care: colorectal cancer. A critical review. Critic Rev Oncol Hematol. 2017;110:81-93.
62. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
63. Pruitt SL, Harzke AJ, Davidson NO, Schootman M. Do diagnostic and treatment delays for colorectal cancer increase risk of death? Cancer Causes Control. 2013;24(5):961-977.
64. Le Cook B, Manning WG. Thinking beyond the mean: a practical guide for using quantile regression methods for health services research. Shanghai Arch Psychiatry. 2013;25(1):55-59.
65. Choi D, Hoffman KA, Kim M-O, McCarty D. A high-resolution analysis of process improvement: use of quantile regression for wait time. Health Serv Res. 2013;48(1):333-347.
66. U.S. Preventive Services Task Force. Final Update Summary: Colorectal Cancer Screening. 2015. https://www.uspreventiveservicestaskforce.org/ Page/Document/UpdateSummaryFinal/colorectal-cancer-screening. Accessed May 11, 2018.
67. Hofmann LJ, Lee S, Waddell B, Davis KG. Effect of race on colon cancer treatment and outcomes in the Department of Defense healthcare system. Dis Colon Rectum. 2010;53(1):9-15.
68. Landrum MB, Keating NL, Lamont EB, Bozeman SR, McNeil BJ. Reasons for underuse of recommended therapies for colorectal and lung cancer in the Veterans Health Administration. Cancer. 2012;118(13):3345-3355.
69. Merkow RP, Bilimoria KY, Sherman KL, McCarter MD, Gordon HS, Bentrem DJ. Efficiency of colorectal cancer care among veterans: analysis of treatment wait times at Veterans Affairs Medical Centers. J Oncol Pract. 2013;9(4): e154-e163.